Compliance / Government & Legislative Affairs / Legal

AdvaMed Comments to HHS Deregulation RFI

AdvaMed submitted public comments in response to HHS’s request for information on eliminating federal regulations that hinder economic growth, innovation, and American competitiveness.

AdvaMed response letter to OMB’s RFI on deregulation, highlighting support for regulatory reform that fosters medical innovation and improved patient care, dated May 12, 2025.
Emerging Policy Response Resources / Government & Legislative Affairs / Legal

AdvaMed Comments to OMB Deregulation RFI

A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.

A group of people sitting at an event and listening to a speaker
In Person

MedTech Compliance Bootcamp

Join AdvaMed & Porzio for this comprehensive compliance bootcamp to better understand the current medtech compliance framework.

Coverage & Payment / Diagnostics / Global & Trade / Government & Legislative Affairs / Health Access / Legal / Regulatory Affairs / Small Business

The Medical Innovation Agenda for the 119th Congress

AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.